Results 31 to 40 of about 273,408 (290)

Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine. [PDF]

PLoS ONE, 2012
Although the use of recombinant hepatitis B virus surface (HBsAg) protein vaccine has successfully reduced global hepatitis B infection, there are still a number of vaccine recipients who do not develop detectable antibody responses.
Guohong Ge, Shixia Wang, Yaping Han, Chunhua Zhang, Shan Lu, Zuhu Huang   +5 more
doaj   +1 more source

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source

Liposome‐mediated DNA vaccination [PDF]

FEBS Letters, 1997
Numerous reports have indicated that intramuscular injection of antigen‐coding naked plasmid DNA can trigger humoral and cell‐mediated protective immunity against infection. This follows DNA uptake by muscle fibres, leading to the expression and extracellular release of the antigen. Here it is shown for the first time that intramuscular immunization of
Gregoriadis, Gregory, Saffie, Roghieh, de Souza, J.Brian   +2 more
openaire   +2 more sources

DNA vaccines [PDF]

Human Vaccines & Immunotherapeutics, 2013
Since the introduction of DNA vaccines two decades ago, this attractive strategy has been hampered by its low immunogenicity in humans. Studies conducted to improve the immunogenicity of DNA vaccines have shown that understanding the mechanism of action of DNA vaccines might be the key to successfully improving their immunogenicity.
Coban, Cevayir, Kobiyama, Kouji, Jounai, Nao, Tozuka, Miyuki, Ishii, Ken J   +4 more
openaire   +2 more sources

Deletion of parasite immune modulatory sequences combined with immune activating signals enhances vaccine mediated protection against filarial nematodes [PDF]

, 2012
<p>Background: Filarial nematodes are tissue-dwelling parasites that can be killed by Th2-driven immune effectors, but that have evolved to withstand immune attack and establish chronic infections by suppressing host immunity. As a consequence, the
AB Fredriksen, AB Pedersen, AE O'Connell, AE Schwab, B de Andres, B Manoury, BL Makepeace, BW Li, C Klotz, C Martin, C Martin, D Abraham, D Abraham, D Horst, D Knox, David W. Taylor, DH Barouch, DL Redmond, E Maraskovsky, G Ahlen, G Nchinda, GT Joseph, HA Farid, HongLin Luo, J Gardon, J Murray, JE Allen, JE Allen, JJ Donnelly, JP Hewitson, Judith E. Allen, KJ Fairlie-Clarke, KJ Ishii, LM Mir, LM Mir, LvG Jørgensen, MD Taylor, MD Taylor, MY Osei-Atweneboana, N Gomez-Escobar, Nick Gray, O Golden, PJ Hotez, R Ihaka, RM Maizels, RT Rwegoshora, S Babayan, S Frontier, S Mendez, S Ramachandran, S Thirugnanam, SA Babayan, SA Babayan, SB Anand, SB Anand, SB Anand, Simon A. Babayan, SM Sumida, Stephen John Davies, W Harnett, WF Gregory, WF Gregory, Y Dash, Y Wu   +63 more
core   +4 more sources

Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses

Viruses
Single-dose, immunogenic DNA (iDNA) vaccines coding for whole live-attenuated viruses are reviewed. This platform, sometimes called immunization DNA, has been used for vaccine development for flavi- and alphaviruses.
Peter Pushko, Igor S. Lukashevich, Dylan M. Johnson, Irina Tretyakova   +3 more
doaj   +1 more source

Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines

Vaccines, 2019
DNA vaccines present one of the most cost-effective platforms to develop global vaccines, which have been tested for nearly three decades in preclinical and clinical settings with some success in the clinic.
Ashish C. Shrestha, Danushka K. Wijesundara, Makutiro G. Masavuli, Zelalem A. Mekonnen, Eric J. Gowans, Branka Grubor-Bauk   +5 more
doaj   +1 more source

DNAVaxDB: the first web-based DNA vaccine database and its data analysis [PDF]

, 2013
Since the first DNA vaccine studies were done in the 1990s, thousands more studies have followed. Here we report the development and analysis of DNAVaxDB ( http://www.violinet.org/dnavaxdb ), the first
He, Yongqun, Li, Xinna, Patel, Mukti, Racz, Rebecca, Xiang, Zuoshuang   +4 more
core   +2 more sources

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]

, 2021
Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G, Frelin, L, Jagya, N, Johansson, M, Maravelia, P, Meuleman, Philip, Ni, Y, Pasetto, A, Pater, L, Pérez, NC, Sällberg, M, Urban, S, Verch, G, Verhoye, Lieven   +13 more
core   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source